Draft concept paper: Models for multi-database pharmacoepidemiologic studies

On behalf of WG3 members, Gianluca Trifirò
Associate Professor of Pharmacology- Dpt. Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy
### Reactivation of WG3 - Inventory of EU data sources and methodological approaches for multisource studies

<table>
<thead>
<tr>
<th>Country</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>IT</td>
<td>University of Messina</td>
</tr>
<tr>
<td>IT</td>
<td>Agenzia Reginale di Sanità della Toscana</td>
</tr>
<tr>
<td>IT</td>
<td>University of Eastern Piedmont</td>
</tr>
<tr>
<td>IT</td>
<td>UNIBO</td>
</tr>
<tr>
<td>IT</td>
<td>MediNeos Observational Research</td>
</tr>
<tr>
<td>IT</td>
<td>TEDDY Network (Fondazione per la Ricerca Farmacologica Gianni Benzi)</td>
</tr>
<tr>
<td>IT</td>
<td>&quot;Vanvitelli&quot; Campania University</td>
</tr>
<tr>
<td>NL</td>
<td>Erasmus MC</td>
</tr>
<tr>
<td>NL</td>
<td>UMC Utrecht</td>
</tr>
<tr>
<td>ES</td>
<td>BIFAP</td>
</tr>
<tr>
<td>ES</td>
<td>EpiChron - Instituto Aragonés de Ciencias de la Salud (IACS)</td>
</tr>
<tr>
<td>FI</td>
<td>EPID Research</td>
</tr>
<tr>
<td>UK</td>
<td>Queen Mary University of London</td>
</tr>
<tr>
<td>UK</td>
<td>Evidera</td>
</tr>
<tr>
<td>UK</td>
<td>UCL School of Pharmacy</td>
</tr>
<tr>
<td>DE</td>
<td>BIPS GmbH (Leibniz Inst. for Prevention Research and Epidem)</td>
</tr>
<tr>
<td>GR</td>
<td>University of Thrace</td>
</tr>
<tr>
<td>PT</td>
<td>Centre for Health Evaluation &amp; Research (CEFAR)</td>
</tr>
<tr>
<td>FR</td>
<td>IMS Health</td>
</tr>
<tr>
<td>FR</td>
<td>University of Lyon</td>
</tr>
</tbody>
</table>
Agenda

• Why revitalizing WG3?
• Outline and aim of the concept paper on multi-database studies
• Work in progress:
  - Information retrieval about multi-DB studies
  - Definitions of dimensions to be evaluated for each specific model
  - Identification of research scenarios
  - Next steps
The landscape of healthcare databases

Examples of large consortia of multi-DB pharmacoepi studies

US
- VSD
- Sentinel
- OHDSI- Observational Health Data Sciences and Informatics (formerly OMOP)

Canada
- CNODES

EU
- EU-ADR: www.euadr-project.org
- ARITMO: www.aritmo-project.org
- SAFEGUARD www.safeguard-diabetes.org
- PROTECT: www.imi-protect.eu
- ADVANCE: www.advance-vaccines.eu
- EMIF: www.imi.europa.eu/content/emif

Global
- GRIP: www.grip-network.org
Different models adopted for multi-database studies - 1

A) Local data extraction and analysis, common protocol

B) Local data extraction and central analysis on patient-level raw data

C) Study-specific local data extraction in a common data model and central analysis

D) General local data extraction in a common data model and central analysis
Different models adopted for multi-database studies - 2

A) Local data extraction and analysis, common protocol

- Data are extracted and analysed locally on the basis of a common protocol;
- Definitions of exposure, outcomes and covariates, analytical programs and reporting formats are standardised according to a common protocol;
- the results of each analysis are shared in an aggregated format and may be pooled together through meta-analysis (e.g. the PROTECT project).
Different models adopted for multi-database studies - 3

B) Local data extraction and central analysis on patient-level raw data

Central analysis of fully anonymized or pseudonymized patient-level raw data extracted based on a common extraction protocol;

This is only possible with a high level of trust among partners, and when data have a very similar structure in the first place, usually being from the same country or very similar countries (e.g. the Scadinavian databases or Italian multi-DB studies).
Different models adopted for multi-database studies - 4

C) Study-specific local data extraction in a common data model and central analysis

✓ Data are extracted from local databases using a study-specific, database-tailored extraction protocol into a common data model and (pre-)processed locally with a common analytic program;

✓ The output of the common analytic program is shared among partners (e.g. EU-ADR project, ARITMO; Safeguards).
D) General local data extraction in a common data model and central analysis

✓ Full set of raw local data is mapped to a common data model;

✓ For each study, data are (pre-)processed locally with a common analytic program (e.g. Sentinel initiative; Observational Health Data Sciences and Informatics (OHDSI) community).
# Sentinel Common Data Model (CDM)

## Administrative

<table>
<thead>
<tr>
<th>Enrollment</th>
<th>Demographic</th>
<th>Dispensing</th>
<th>Encounter</th>
<th>Diagnosis</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
</tr>
<tr>
<td>Enrollment start &amp; end dates</td>
<td>Birth date</td>
<td>Dispensing date</td>
<td>Service date(s)</td>
<td>Service date(s)</td>
<td>Service date(s)</td>
</tr>
<tr>
<td>Drug coverage</td>
<td>Sex</td>
<td>National drug code (NDC)</td>
<td>Encounter ID</td>
<td>Encounter type &amp; provider</td>
<td>Encounter type &amp; provider</td>
</tr>
<tr>
<td>Medical coverage</td>
<td>ZIP code</td>
<td>Days supply</td>
<td>Facility</td>
<td>Diagnosis code &amp; type</td>
<td>Diagnosis code &amp; type</td>
</tr>
<tr>
<td>Medical record availability</td>
<td>Etc.</td>
<td>Amount dispensed</td>
<td>Etc.</td>
<td>Principal discharge diagnosis</td>
<td>Etc.</td>
</tr>
</tbody>
</table>

## Clinical

<table>
<thead>
<tr>
<th>Lab Result</th>
<th>Vital Signs</th>
<th>Death</th>
<th>Cause of Death</th>
<th>State Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
<td>Person ID</td>
</tr>
<tr>
<td>Result and specimen collection dates</td>
<td>Measurement date and time</td>
<td>Death date</td>
<td>Cause of death</td>
<td>Vaccination date</td>
</tr>
<tr>
<td>Test type, immediacy &amp; location</td>
<td>Height and weight</td>
<td>Source</td>
<td>Source</td>
<td>Admission Type</td>
</tr>
<tr>
<td>Logical Observation Identifiers Names and Codes (LOINC ®)</td>
<td>Diastolic &amp; systolic BP</td>
<td>Confidence</td>
<td>Confidence</td>
<td>Vaccine code &amp; type</td>
</tr>
<tr>
<td>Test result &amp; unit</td>
<td>Tobacco use &amp; type</td>
<td>Etc.</td>
<td>Etc.</td>
<td>Provider</td>
</tr>
</tbody>
</table>
### Different models adopted for multi-database studies - 6

<table>
<thead>
<tr>
<th>Model</th>
<th>Responsibility for data management</th>
<th>Responsibility for data analysis</th>
<th>Output to be shared with partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Local</td>
<td>Local</td>
<td>Final estimates</td>
</tr>
<tr>
<td>B</td>
<td>Central</td>
<td>Central</td>
<td>Raw data</td>
</tr>
<tr>
<td>C</td>
<td>Local, study-specific</td>
<td>Central</td>
<td>Analytic dataset or aggregated intermediate dataset or final estimates (according to agreement among partners)</td>
</tr>
<tr>
<td>D</td>
<td>Local once every data update, then central</td>
<td>Central</td>
<td>Analytic dataset or aggregated intermediate dataset or final estimates (according to agreement among partners)</td>
</tr>
</tbody>
</table>
Concept paper outline

Aims

• Collect relevant examples of multi-DB initiatives;
• Identify relevant dimensions to evaluate feasibility, performance and scientific soundness of different multi-DB network models;
• Compare the four models with respect to the dimensions identified;
• Create a decision model /framework that would allow researchers deciding which model is better for a particular type of research scenario.
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) survey of methodologies for European Union publicly funded multi-database safety studies

Current practice in European Union multi-database pharmacoepidemiology research

Coordinated by Miriam Sturkenboom on behalf of WG3
Key findings

- Survey of the research coordinators of consortia funded under FP7 - Health 2007 – 2013 and/or European Medicines Agency and/or IMI projects aimed at conducting multi-DB studies (N=16/18 projects);

- N. of databases used in individual projects ranged from 2 to 11 and 8 of the projects (44%) involved pooling data from different databases;

- Large heterogeneity of methods used to combine data from multiple databases; it has yet to be established if a single model is the best approach;
EncePP survey on EU-funded multiple database studies (n=16)

Pooling of data for analysis

- Pooling of elaborated individual patient level data
- Meta-analysis of coefficients
- Central pooling of raw data
- Not specified
Key findings

- Survey of the research coordinators of consortia funded under FP7 - Health 2007 – 2013 and/or European Medicines Agency and/or IMI projects aimed at conducting multi-DB studies (N=16/18 projects);

- N. of databases used in individual projects ranged from 2 to 11 and 8 of the projects (44%) involved pooling data from different databases;

- Large heterogeneity of methods used to combine data from multiple databases; it has yet to be established if a single model is the best approach;

- To contact again all coordinators with a structured questionnaire to inquire about: 1) Common data model; 2) Common analytics; 3) Governance; 4) Sustainability; 5) Publications; 6) Lessons learned.
1. Collected relevant papers from experts (SG and WG3 members) through dropbox folder
2. Execute a Pubmed search using specific string
3. Assess sensitivity
4. If sensitivity <80%, search for new keywords and repeat from (2)
Expert opinion and available publications on multiDB studies

– Assess whether proposed models are exhaustive and accordingly categorize different initiatives into proposed models;

– Create a list of relevant dimensions to be evaluated: (a) flexibility; b) need for initial investments; c) velocity in executing many studies; d) sustainability; e) risks of errors/misunderstandings; f) legal constraints; g) ability in addressing diversity of local data; h) others);

– Score each model with respect to the relevant dimensions in relation to different research scenarios.
Research scenarios – 1

Why?

“Create a decision model /framework that would allow researchers deciding which model is better for a particular type of research scenario (e.g. periodic safety monitoring, drug utilisation studies, disease epidemiology studies, drug safety signal confirmation studies, .....)”
Research scenarios – 2

How?

- **For whom** research scenarios have to be relevant?

- Involvement of **regulatory agencies**, which one? (EMA - EU Member States; Health Canada; FDA; Asian and other Countries regulatory agencies)

- How much **comprehensive and specific** (e.g. drug utilisation studies vs. studies on exposure to teratogenic drugs in pregnancy) has to be the list of research scenarios?

- Stand alone publication!

- List of research scenarios has to be considered **dynamic** as priorities of post-marketing assessment evolve over time.
Research scenarios – 3

Planned actions

- Survey of ENCePP partners through electronic questionnaires (google form) which was pilot tested by WG3 members;

- Revise studies in the EU PAS Register;

- Interview of regulatory agencies and coordinators of most relevant international multi-DB initiatives to prioritize the list of proposed research scenarios potentially requiring multiple-DB studies.
Survey of ENCePP partners through electronic questionnaires - 1

Which type of regulatory decisions can profit from evidence generated by multi-database studies?

This survey is conducted in the context of ENCePP Working Group 3 “Inventory of EU data sources and methodological approaches for multi-source studies”. The survey is aimed at identifying what are the research questions asked by regulators that can be addressed by conducting observational multi-database studies. More specifically, we are interested in getting a better understanding of the value of multi-database pharmacoepidemiology studies regarding different types of drug-related issues which requires further investigation in post-marketing setting.

Multi-database studies are studies which are carried out using at least two healthcare databases that cannot be linked with each other at individual level.

Please answer the following questions based on your personal experience.
Survey of ENCePP partners through electronic questionnaires - 2

1. Do you currently work mainly in
   - Academia
   - Contract Research Organization
   - Public research agency
   - Altro: __________________________

2. Are you currently participating, or have you participated in the past two years, in a committee which advises or takes regulatory decisions?
   - Yes
   - No

3. Have you ever been involved in multi-database pharmacoepidemiology studies?
   - Yes
   - No
Survey of ENCePP partners through electronic questionnaires - 3

- Irrespective of your involvement in such studies, what type of research questions do you think can profit from the evidence generated by multi-database studies?

  Drug Utilization studies
  Effectiveness assessment
  Risk assessment
  Disease epidemiology
Survey of ENCePP partners through electronic questionnaires - 4

• Drug Utilization studies
  – Implementation of risk minimization measures
  – Underdosage or overdosage
  – Adherence and persistence to chronic treatments
  – Use of contraindicated drugs in special populations (patients with renal or hepatic impairment, pregnancy or breastfeeding)
  – Off label use of drugs
  – Uptake of generics and biosimilars
  – Appropriate use of high cost drugs
  – Appropriate use of orphan drugs
  – Vaccination coverage
• Effectiveness assessment
  – Periodic effectiveness monitoring
  – Effectiveness evaluation in special populations (e.g. children, pregnant women, immunocompromised)
  – Long term effectiveness
  – Comparative effectiveness of drugs with same indication
  – Comparative effectiveness of generics/biosimilars vs. originators
  – Effectiveness of orphan drugs
  – Vaccine effectiveness
• Risk assessment
  – Periodic safety monitoring
  – Signal detection
  – Signal strengthening
  – Signal confirmation
  – Safety evaluation in special populations (e.g. children, pregnant women, immunocompromised
  – Long-term safety
  – Rare adverse drug reactions
  – Effects of risks minimization measures
  – Adverse drug reactions due to drug-drug interactions
  – Comparative safety of drugs with same indication
  – Comparative safety of generics/biosimilars vs. originators
  – Safety of orphan drugs
  – Vaccine safety
Overall, can you score (from 1= “no or limited value” to 5= “greatest value”) how much the results of multiple database pharmacoepidemiology studies can drive regulatory decisions?
The European Union electronic Register of Post-Authorisation Studies (EU PAS Register)

The EU PAS Register® is a publicly available register of non-interventional post-authorisation studies (PAS).

The Register has a focus on observational research, and its purpose is to:

- increase transparency,
- reduce publication bias,
- promote the exchange of information and facilitate collaboration among stakeholders, including academia, sponsors and regulatory bodies,
- ensure compliance with EU pharmacovigilance legislation requirements.
EU PAS Register - 2

Population age:
- Preterm newborns
- Term newborns (0-27 days)
- Infants and toddlers (28 days - 23 months)
- Children (2 - 11 years)
- Adolescents (12 - 17 years)

Other population:
- Renal impaired
- Hepatic impaired
- Immunocompromised
- Pregnant women

Scope of the Study:
- Disease epidemiology
- Risk assessment
- Drug utilisation study
- Effectiveness evaluation
- Other
Next steps

• Extended survey of coordinator of EU-funded multi-DB studies
• Systematic review of key publications about multi-DB pharmacoepi studies
• Definition of dimensions to be evaluated
• ENCePP partner survey on research scenarios
• Analysis of studies available in EU PAS register
• Interview through semi-structured questionnaire to key regulators and international experts
Thanks for the attention

Gianluca Trifirò
trifirog@unime.it